Literature DB >> 8640849

Autoantibodies against p53 are not increased in human ascites and pleural effusions.

R Munker1, O Stötzer, M Darsow, S Classen, A Lebeau, W Wilmanns.   

Abstract

Mutated human p53 may give rise to the formation of autoantibodies and may be a marker for a worse prognosis. We speculated that ascites or pleural effusions may enhance the formation of such autoantibodies in cancer patients and, therefore, we measured the presence of autoantibodies in the ascites or pleural effusion of 40 patients with advanced malignancies. As controls, p53 autoantibodies were measured in 15 patients with effusions who did not have a malignancy. Using a specific enzyme-linked immunosorbent assay, p53 autoantibodies could only be detected in the effusions of 5/40 patients (12.5%) with known malignancies. The formation of autoantibodies did not correlate with the presence or absence of tumor cells in the effusion. The effusions of the patients without tumor were all negative for p53 autoantibodies. Our study shows that malignant or reactive effusions do not stimulate the local or systemic production of autoantibodies against p53.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8640849     DOI: 10.1007/s002620050271

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  3 in total

Review 1.  Clinical utility of anti-p53 auto-antibody: systematic review and focus on colorectal cancer.

Authors:  Aravind Suppiah; John Greenman
Journal:  World J Gastroenterol       Date:  2013-08-07       Impact factor: 5.742

Review 2.  Mutant p53 as an Antigen in Cancer Immunotherapy.

Authors:  Navid Sobhani; Alberto D'Angelo; Xu Wang; Ken H Young; Daniele Generali; Yong Li
Journal:  Int J Mol Sci       Date:  2020-06-08       Impact factor: 5.923

Review 3.  Prognostic Role of Serum Antibody Immunity to p53 Oncogenic Protein in Ovarian Cancer: A Systematic Review and a Meta-Analysis.

Authors:  Marica Garziera; Marcella Montico; Ettore Bidoli; Simona Scalone; Roberto Sorio; Giorgio Giorda; Emilio Lucia; Giuseppe Toffoli
Journal:  PLoS One       Date:  2015-10-09       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.